middle.news
Chimeric Therapeutics Reports 82% Stable Disease in CHM CDH17 Phase 1/2 Trial
8:27am on Monday 1st of June, 2026 AEST
•
Biotechnology
Read Story
Chimeric Therapeutics Reports 82% Stable Disease in CHM CDH17 Phase 1/2 Trial
8:27am on Monday 1st of June, 2026 AEST
Key Points
82% stable disease rate in evaluable patients
Robust CAR-T cell expansion and persistence observed
Tolerable safety profile with manageable adverse events
Dose Level 3 enrolment ongoing with Phase 2 dose pending
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE